Alcohol Use Disorder Diagnoses Among Individuals Who Take HIV Preexposure Prophylaxis

作者：Anton L.V. Avanceña, Godwin Okoye, Rishit Yokananth, Aliza Norwood, Phillip W. Schnarrs · 发表于：JAMA Network Open · 年份：2025 · DOI：10.1001/jamanetworkopen.2025.7295 · 被引用次数：7 · 研究领域：HIV/AIDS Research and Interventions、HIV, Drug Use, Sexual Risk、Pneumocystis jirovecii pneumonia detection and treatment

Importance: Alcohol use disorder (AUD) may negatively affect preexposure prophylaxis (PrEP) adherence and continuation, reducing PrEP effectiveness. Objective: To estimate the prevalence of and and factors associated with AUD diagnoses among commercially insured individuals who take PrEP. Design, Setting, and Participants: This retrospective cohort study used US health care claims data to identify individuals aged 16 to 64 years who received at least 1 new PrEP prescription between January 1, 2014, to December 31, 2021. Data were analyzed from June 2024 to February 2025. Exposure: Sociodemographic characteristics included patient age, sex, geographic location, employment status, and type of health insurance. Clinical characteristics included sexually transmitted infection (STI) diagnosis and testing, use of psychotherapy services, and diagnosis of other mental health conditions. Main Outcomes and Measures: The main outcome was an AUD diagnosis within 6 months before or after the date of PrEP initiation. Among individuals with an AUD diagnosis, receipt of medications for AUD (MAUDs), including Food and Drug Administration (FDA)-approved MAUDs (acamprosate, disulfiram, and oral and injectable naltrexone) and non-FDA-approved MAUDs (baclofen, gabapentin, and topiramate) was determined. Results: The study cohort included 43 913 individuals receiving PrEP (mean [SD] age, 35.8 [10.94] years; 35 027 [90.1%] male assigned at birth). There were 6274 individuals (14.29%) who had an AUD...